CD226 Ligation Protects Against EAE by Promoting IL-10 Expression Via Regulation of CD4+ T Cell Differentiation.
Rong Zhang,Hanyu Zeng,Yun Zhang,Kun Chen,Chunmei Zhang,Chaojun Song,Liang Fang,Zhuwei Xu,Kun Yang,Boquan Jin,Qintao Wang,Lihua Chen
DOI: https://doi.org/10.18632/oncotarget.7834
2016-01-01
Oncotarget
Abstract:Treatment targeting CD226 can ameliorate experimental autoimmune encephalomyelitis (EAE), the widely accepted model of MS. However, the mechanisms still need to be elucidated. Here we showed that CD226 blockage by anti-CD226 blocking mAb LeoA1 efficiently promoted IL-10 production in human peripheral blood monocytes (PBMC) or in mixed lymphocyte culture (MLC) system, significantly induced the CD4+IL-10+ T cell differentiation while suppressing the generation of Th1 and Th17. Furthermore, CD226 pAb administration in vivo reduced the onset of EAE in mice by promoting IL-10 production and regulating T cell differentiation. Concomitantly, the onset and severity of EAE were reduced and the serum IL-10 expression levels were increased in CD226 knockout mice than that in control mice when both received EAE induction. These novel findings confirmed that CD226 played a pivotal role in mediating autoimmune diseases such as EAE. Furthermore, to our knowledge, we show for the first time that IL-10 is an important contributor in the inhibitory effects of CD226 ligation on EAE.
What problem does this paper attempt to address?